220 related articles for article (PubMed ID: 31468535)
1. S-100B as an extra selection tool for FDG PET/CT scanning in follow-up of AJCC stage III melanoma patients.
Deckers EA; Wevers KP; Muller Kobold AC; Damude S; Vrielink OM; van Ginkel RJ; Been LB; van Leeuwen BL; Hoekstra HJ; Kruijff S
J Surg Oncol; 2019 Nov; 120(6):1031-1037. PubMed ID: 31468535
[TBL] [Abstract][Full Text] [Related]
2. Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma.
Kruijff S; Bastiaannet E; Brouwers AH; Nagengast WB; Speijers MJ; Suurmeijer AJ; Hospers GA; Hoekstra HJ
Ann Surg Oncol; 2012 Feb; 19(2):620-6. PubMed ID: 21861214
[TBL] [Abstract][Full Text] [Related]
3. S-100B concentrations predict disease-free survival in stage III melanoma patients.
Kruijff S; Bastiaannet E; Kobold AC; van Ginkel RJ; Suurmeijer AJ; Hoekstra HJ
Ann Surg Oncol; 2009 Dec; 16(12):3455-62. PubMed ID: 19636631
[TBL] [Abstract][Full Text] [Related]
4. The association between active tumor volume, total lesion glycolysis and levels of S-100B and LDH in stage IV melanoma patients.
Deckers EA; Kruijff S; Brouwers AH; van der Steen K; Hoekstra HJ; Thompson JF; Vállez García D; Wevers KP
Eur J Surg Oncol; 2020 Nov; 46(11):2147-2153. PubMed ID: 32819759
[TBL] [Abstract][Full Text] [Related]
5. The value of pre operative S-100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection.
Kruijff S; Bastiaannet E; Speijers MJ; Kobold AC; Brouwers AH; Hoekstra HJ
Eur J Surg Oncol; 2011 Mar; 37(3):225-32. PubMed ID: 21277729
[TBL] [Abstract][Full Text] [Related]
6. Value of tumour marker S-100B in melanoma patients: a comparison to 18F-FDG PET and clinical data.
Reinhardt MJ; Kensy J; Frohmann JP; Willkomm P; Reinhold U; Grünwald F; Biersack HJ; Bender H
Nuklearmedizin; 2002 Jun; 41(3):143-7. PubMed ID: 12109034
[TBL] [Abstract][Full Text] [Related]
7. S-100B and FDG-PET/CT in therapy response assessment of melanoma patients.
Strobel K; Skalsky J; Steinert HC; Dummer R; Hany TF; Bhure U; Seifert B; Pérez Lago M; Joller-Jemelka H; Kalff V
Dermatology; 2007; 215(3):192-201. PubMed ID: 17823514
[TBL] [Abstract][Full Text] [Related]
8. Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma.
Strobel K; Bode B; Dummer R; Veit-Haibach P; Fischer DR; Imhof L; Goldinger S; Steinert HC; von Schulthess GK
Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1774-82. PubMed ID: 19495748
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B.
Strobel K; Dummer R; Steinert HC; Conzett KB; Schad K; Lago MP; Soyka JD; Veit-Haibach P; Seifert B; Kalff V
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1786-95. PubMed ID: 18458901
[TBL] [Abstract][Full Text] [Related]
10. The use of FDG-PET/CT to detect early recurrence after resection of high-risk stage III melanoma.
Stahlie EHA; van der Hiel B; Stokkel MPM; Schrage YM; van Houdt WJ; Wouters MW; van Akkooi ACJ
J Surg Oncol; 2020 Dec; 122(7):1328-1336. PubMed ID: 32783266
[TBL] [Abstract][Full Text] [Related]
11. Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B.
Strobel K; Skalsky J; Kalff V; Baumann K; Seifert B; Joller-Jemelka H; Dummer R; Steinert HC
Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1366-75. PubMed ID: 17390135
[TBL] [Abstract][Full Text] [Related]
12. Utility of FDG PET/CT and brain MRI in melanoma patients with increased serum S-100B level during follow-up.
Aukema TS; Olmos RA; Korse CM; Kroon BB; Wouters MW; Vogel WV; Bonfrer JM; Nieweg OE
Ann Surg Oncol; 2010 Jun; 17(6):1657-61. PubMed ID: 20151211
[TBL] [Abstract][Full Text] [Related]
13. Whole body PET/CT in the follow-up of asymptomatic patients with stage IIB-IIIB cutaneous melanoma
Koskivuo I; Kemppainen J; Giordano S; Seppänen M; Veräjänkorva E; Vihinen P; Minn H
Acta Oncol; 2016 Nov; 55(11):1355-1359. PubMed ID: 27553064
[TBL] [Abstract][Full Text] [Related]
14.
Jaeger ZJ; Williams GA; Chen L; Mhlanga JC; Cornelius LA; Fields RC
J Surg Oncol; 2022 Mar; 125(3):525-534. PubMed ID: 34741547
[TBL] [Abstract][Full Text] [Related]
15.
Lawal I; Lengana T; Ololade K; Boshomane T; Reyneke F; Modiselle M; Vorster M; Sathekge M
Nuklearmedizin; 2017 Jun; 56(3):83-89. PubMed ID: 28154879
[TBL] [Abstract][Full Text] [Related]
16. Role of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for the Detection of Recurrent Disease after Treatment of Malignant Melanoma.
Lee JW; Nam SB; Kim SJ
Oncology; 2019; 97(5):286-293. PubMed ID: 31437839
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
18. F-18 fluorodeoxyglucose positron emission tomography/computed tomography in conjunctival melanoma with recurrence.
Jain A; John AR; Kishore B; Vishnoi MG; Pandit AG; Sharma A; Jaimini A; Jain M; Singh A
J Cancer Res Ther; 2020 Dec; 16(Supplement):S240-S242. PubMed ID: 33380688
[TBL] [Abstract][Full Text] [Related]
19. Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
Rayamajhi S; Balachandran A; Katz M; Reddy A; Rohren E; Bhosale P
Abdom Radiol (NY); 2018 Feb; 43(2):505-513. PubMed ID: 28900703
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Prognostic Value of
Albano D; Familiari D; Fornito MC; Scalisi S; Laudicella R; Galia M; Grassedonio E; Ruggeri A; Ganduscio G; Messina M; Spada M; Midiri M; Alongi P
Curr Radiopharm; 2020; 13(1):42-47. PubMed ID: 31595860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
